Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

4-NEMD

From Wikipedia, the free encyclopedia
(Redirected from C15H14N2)
4-NEMD
Clinical data
ATC code
  • None
Identifiers
  • (S)-4-(1-Naphthalen-1-ylethyl)-1H-imidazole
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H14N2
Molar mass222.291 g·mol−1
3D model (JSmol)
  • CC(C1=CC=CC2=CC=CC=C21)C3=CN=CN3
  • InChI=1S/C15H14N2/c1-11(15-9-16-10-17-15)13-8-4-6-12-5-2-3-7-14(12)13/h2-11H,1H3,(H,16,17)/t11-/m0/s1 checkY
  • Key:DZSQSLQSMKNVBV-NSHDSACASA-N checkY
 X markNcheckY (what is this?)  (verify)

4-NEMD is a potent sedative drug which acts as a selective alpha-2 adrenergic receptor agonist. It is closely related to dexmedetomidine but is several times more potent.[1] Like other alpha-2 agonists, it produces sedative and muscle relaxant effects but without producing respiratory depression. It is not currently used in medicine, but has been researched as the basis for a potential new generation of alpha-2 agonist drugs,[2][3] which may have selectivity for the different subtypes of the alpha-2 receptor.[4] It has two isomers, with the (S) isomer being the more potent, as with medetomidine.[5] 4-NEMD was also investigated by the United States military as an anesthetic agent, most likely for use in surgery, but possibly also for use as a non-lethal incapacitating agent, although this has not been officially confirmed.[6]

References

[edit]
  1. ↑ Hong SS, Romstedt KJ, Feller DR, Hsu FL, Cupps TL, Lyon RA, Miller DD (July 1994). "A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic receptors". Journal of Medicinal Chemistry. 37 (15): 2328–33. doi:10.1021/jm00041a011. PMID 7914537.
  2. ↑ Zhang X, Yao XT, Dalton JT, Shams G, Lei L, Patil PN, et al. (July 1996). "Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene derivatives of medetomidine". Journal of Medicinal Chemistry. 39 (15): 3001–13. doi:10.1021/jm9506074. PMID 8709134.
  3. ↑ Zhang X, De Los Angeles JE, He MY, Dalton JT, Shams G, Lei L, et al. (September 1997). "Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket"". Journal of Medicinal Chemistry. 40 (19): 3014–24. doi:10.1021/jm960642q. PMID 9301663.
  4. ↑ Lalchandani SG, Zhang X, Hong SS, Liggett SB, Li W, Moore BM, et al. (January 2004). "Medetomidine analogs as selective agonists for the human alpha2-adrenoceptors". Biochemical Pharmacology. 67 (1): 87–96. doi:10.1016/j.bcp.2003.08.043. PMID 14667931.
  5. ↑ Hong SS, Romstedt KJ, Feller DR, Hsu FL, George C, Cupps TL, et al. (1992). "Resolution and adrenergic activities of the optical isomers of 4-[1-(1-naphthyl)ethyl]-1H-imidazole". Chirality. 4 (7): 432–8. doi:10.1002/chir.530040706. PMID 1361151.
  6. ↑ US 5151526, Hsu FL, Ashman WP, "4-(1-(1-naphthalenyl)ethyl)-1H- imidazole, method of making and use as an anesthetic agent."
Retrieved from "https://en.wikipedia.org/w/index.php?title=4-NEMD&oldid=1329443495"